Browse by Audience
Skip to content
Papers of the Week
Two-year, real-world erenumab persistence and quality of life data in 82 pooled patients with abrupt onset, unremitting, treatment refractory headache and a migraine phenotype: New daily persistent headache or persistent post-traumatic headache in the majority of cases.
Authors
Buture A, Tomkins EM, Shukralla A, Troy E, Conaty K, Macken E, Lonergan R, Melling J, Long N, Birrane K, Shaikh E, Goadsby PJ, Ruttledge MHAbstract
Patients diagnosed with New Daily Persistent Headache and Persistent Post-Traumatic Headache belong to a heterogeneous group of primary and secondary headache disorders, with the common clinical feature that these conditions start abruptly, continue unabated, and are refractory to conventional migraine preventive treatments.